Stock Analiz

Silo Pharma, Inc. SILO

Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026

$1.84Market cap $4M
Open the interactive analysis →

Silo Pharma, Inc. (SILO) is a healthcare company listed in the US with a market value of about $4M. In the twelve months to September 30, 2026 it had revenue of $36052 and net income of -$4M, a net margin of -10319.0%.

Its overall Stock Analiz score is 1.6 out of 5 (weak). The strongest part is financial health (4/5); the weakest is shareholder returns (0/5).

Key numbers: a P/E of 0.3, 5-year revenue growth of 12% a year, a 5-year average ROIC of -47%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 100% below the current price.

About Silo Pharma

Silo Pharma is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $40569 in 2019 to $72102 in 2025, growth of about 10.1% a year. It was profitable in 2 of the last 10 years in our data. Its share count rose by 267% over three years (dilution for shareholders). It spends 2997% of revenue on research and development.

Score: 1.6 / 5

Value2/5
Future growth1/5
Track record1/5
Financial health4/5
Shareholder returns0/5

Checks passed

  • P/E below 25
  • P/E below the industry median
  • Strong R&D investment or growth above 20%
  • 5-year revenue growth above 8% a year
  • More cash than debt, or low debt to equity
  • Interest covered more than 5 times
  • Debt below 3 years of free cash flow
  • Liabilities below 60% of assets

Checks not passed

  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year

Valuation

P/E (TTM)0.3
Forward P/E—
P/FCF—
P/S119.4
P/B0.5
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield—
Shareholder yield0.0%
Intrinsic value vs. price−100%

Growth and quality

Revenue growth (1 yr)0.0%
Revenue growth (5 yrs, per year)12.0%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-5627.4%
ROIC (5-yr avg.)-46.9%
Profitable years (of last 10)2
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172012
Revenue$36052$72102$72102$72102$72102—$40923$40569———
Net income-$4M-$4M-$4M-$4M-$4M$4M-$3M-$1M-$969463$356536-$39446
Free cash flow——————————-$21473
EPS (diluted)$5.88$-0.50$-1.19$-1.20$-1.71$2.00$-2.50$-2.00$-1.00$0.50$0.00
Net margin-10319.0%-5863.5%-6092.6%-5132.6%-5420.9%—-7422.5%-2497.7%———
ROIC—-53.6%-73.8%-49.3%-27.7%-30.1%-133.8%-1885.5%-115.2%-32.2%—

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

What is Silo Pharma’s P/E ratio?

About 0.3, based on the last twelve months of diluted earnings per share.

Is Silo Pharma stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 100% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Silo Pharma pay a dividend?

Not currently.

Is Silo Pharma a good stock to buy?

We do not give buy or sell advice. Silo Pharma scores 1.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.